Small Pharmaceuticals
Market Cap
₹20,939 ₹20,939 Cr.
P/E
31.47
PEG
2.91
PEG = P/E ÷ 5yr Forward EPS CAGR
5yr Forward EPS CAGR Thesis - Base Case

- US injectables front-end and COL-II commissioning are the linchpin: bull case requires strong direct-hospital contract wins, bear case if COL-II faces >12-month delay- Emerging-market growth depends on Mexico/Chile ramp; currency crises or political disruption could push EM growth below 6% CAGR
- Management's capex execution credibility remains the wedge between scenarios, as timeline slippage would shift probabilities toward the bear case

Key Ratios

Debt to Equity
Debt to Equity
0.00
Div Yield (%)
Div Yield (%)
0.29
Individual < 2 lac
Individual < 2 lac
12.14 %
Institutions
Institutions
8.24 %
Market cap
Market cap
20,939 Cr
No. of Shareholders
No. of Shareholders
94,385
OPM (%)
OPM (%)
34.83 %
PE
PE
31.47
Prom Holding
Prom Holding
70.57 %
ROCE (%)
ROCE (%)
22.01
ROE (%)
ROE (%)
17.88
Sales
Sales
2,287 Cr
  • Caplin Point Labs.
  • Gufic Biosciences
  • Gland Pharma
  • TJI Pharma - Small Cap
Last updated on 12 Aug 2026
  • Caplin Point is a 100% export generics maker for LatAm, US and Africa via own warehouses; shifted from unbranded wholesale toward branded generics
  • Earnings from LatAm generics base plus US sterile injectables; product sales dominate, milestone and profit-share round out
  • Per management, edge is owned LatAm distribution, asset-light outsourcing with selective integration and automation-led compliance
  • Building oncology API, Puducherry oral solids and new sterile lines toward backward integration and captive supply
  • Net-cash, accrual-funded expansion; receivables stretched to 136 days as cost of forward integration
  • In mid-expansion stabilisation before larger markets pay off; near-term rides on Mexico-Chile and US own-label ramp
  • Three-quarters LatAm, export-only; first credit provision taken in FY26
  • First Vizag DMF and validations in 2026/27
    starts captive API leg toward 60% backward integration; 2-year margin lag per management
  • Thervoy oncology API Q3FY27
    first oncology API capacity comes online
  • Puducherry oral solids plant Q3FY27 (was Q4FY26)
    adds oral-solids capacity for Mexico, Brazil, US and EU
  • COL-II sterile lines Dec 2026 first lines, Q4FY27 rest
    five isolator sterile lines come online
  • Mexico and Chile tender execution 24mo from May 2026
    $4m Mexico and $10m Chile tenders convert; own facility build follows
Price Range

See where the stock is trading versus its 52-week high and low.

Low
1502
52W Range
High
2874
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

8 Yes

Positive for this company

3 Neutral

Neutral for this company

6 No

Negative for this company

0 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Distribution Channel

Manufacturing Break-Up

Operational Metrics

    Select a Metric
    • Number of ANDA's Filed in USA (.)
    • Number of ANDA's Approved By USFDA (.)
    • R&D as a % of Total Sales (%)

    Peer Comparison

    Corporate Actions

    Consolidated
    DATE
    DETAILS
    Show More
    Show Less
    Show More
    Show Less

    FAQs on Caplin Point Laboratories Ltd. Business

    Established in 1990, Caplin Point Laboratories is a mid-sized company in India manufacturing APIs, finished formulations, and engaging in research & development, clinical research, and global marketing.

    Caplin Point Labs. major competitors are Gufic Biosciences, Gland Pharma, Pfizer, Eris Lifesciences, Astrazeneca Pharma, Jubilant Pharmova, Alembic Pharma.
    Market Cap of Caplin Point Labs. is ₹20,797 Crs.
    While the median market cap of its peers are ₹17,002 Crs.

    Caplin Point Labs. seems to be financially stable compared to its competitors.
    The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

    Company Filing

    Discussions & Analysis

    Ideas Dashboard
    Results
    Timeline
    Watchlist
    Portfolio
    Alerts
    Stock Screener
    Market
    Raw Material